Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP) regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role in primary management of ovarian cancer. This review summarizes previous and ongoing studies regarding the use of HIPEC in the management of ovarian cancer.

Original languageEnglish
Article number296
Issue number9
StatePublished - Sep 1 2018


  • Cytoreductive surgery
  • Heated intraperitoneal chemotherapy (hipec)
  • Interval cytoreduction
  • Intraperitoneal chemotherapy (ip)
  • Ovarian cancer
  • Secondary cytoreduction


Dive into the research topics of 'Heated intraperitoneal chemotherapy in the management of advanced ovarian cancer'. Together they form a unique fingerprint.

Cite this